Abetes was induced by intraperitoneal injection of streptozotocin into 8-week-old C57BL/6 male mice. At eight weeks just after the induction of diabetes, the animals were distributed into 7 groups: manage non-diabetic mice and diabetic mice getting two successive intracavernous injections of HEPES-buffered saline (HBS, days -3 and 0; 20 L) or ESC-JOURNAL OF EXTRACELLULAR VESICLESderived EV-mimetic NVs (ESC-NVs, days -3 and 0; 0.1 g, 0.five g, 1 g, two g, or 5 g in 20 L of HBS, respectively). Two week right after treatment, we measured erectile function by electrical stimulation from the cavernous nerve. The penis was then harvested for histological and biochemical research. We also examined the effects of ESC-Exo in principal cultured mouse cavernous endothelial cells (MCEC) and pericytes (MCP) in vitro; and in cultured aortic ring and key pelvic ganglion (MPG) ex vivo. Results: Intracavernous injections of ESC-NVs significantly improved erectile function in diabetic mice, which reached up to 90 of control values. ESC-NVs induced important restoration of cavernous contents of endothelial cells, smooth muscle cells, pericytes, and neuronal cells in diabetic situation. Additionally, ESCNVs promoted micro-vascular sprouting from aortic ring and accelerated tube formation in major cultured MCEC and MCP mono-culture or co-culture technique in vitro. Summary/Conclusion: ESC-NVs effectively restored erectile function through enhanced cavernous angiogenesis and neural regeneration in diabetic mice. It will be a better tactic to make use of ESC-NVs than ESCs for the PPAR Purity & Documentation treatment of retractable erectile dysfunction though it remains to be solved for future clinical application of ESCs.PT12.Human adipose tissue-derived mesenchymal stem cell exosomes for the treatment of liver fibrosis Sol Shin, Soyoung Son, Gyeongtaek Lim, Seunglee Kwon and Jaehyung Parkaof A-exo was determined by BCA assay. The impact of A-Exo on the expression level of -SMA was evaluated by IF analysis. Mice were received thioacetamide intraperitoneally. Fluorescently labelled A-exo was administered to mice and whole-body fluorescence was observed as a way to evaluate the in vivo distribution. The therapeutic efficacy of A-exo was determined by measuring the level of ALT, ALP, TBIL and TP in blood of mice. A-exo was injected intravenously three instances and blood was collected soon after final injection. Results: When hepatic stellate cells had been activated with TGF-1, the expression amount of -SMA was significantly enhanced. While, the level was remarkably decreased according to the remedy concentration of A-Exo. A-exo therapy significantly decreased expression mRNA of pro-fibrogenic marker: -SMA, Collagen I and MMP-2. After systemic administration of exosome, a substantial accumulation of A-Exo at liver was observed in each the regular and mice model of liver fibrosis. Moreover, liver function of A-exo treated group was restored to typical. These results showed A-exo had the higher therapeutic efficacy. Summary/Conclusion: Within this study, we investigate the possible of stem cell-derived MMP-13 manufacturer exosome because the new therapeutic strategy for liver fibrosis treatment. Aexo has equivalent bioactive capacity to its origin cell, mesenchymal stem cell. The valuable impact of A-exo was confirmed in vitro and in vivo tests. The superior therapeutic efficacy was displayed in A-exo treated mouse group.PT12.HucMSC exosome confer protection against ultraviolet radiation induced acute photodamage via modulation of SIRT1 pathway Peipei.